Search the database for deliberate release of GM medicinal products

Displaying 1 - 2 of 2
EU record number Title Company / Sponsor Treated organism Genetic modification
B/BE/02/B7 Phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in patients with metastatic Renal Cell Carcinoma (RCC) Transgene S.A. Humans sequences coding for the human MUC-1 antigen and IL-2
Only notified under the "contained use" procedure. Dossier submitted on . A European and Canadian multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 in patients with stable angina Schering N.V./S.A. Humans human FGF-4

© Sciensano - Version 1.0 (20260902.1)